Beyond the Hype: How Global Pharma Is Strategically Positioning Around Organoids and New Approach Methodologies (NAMs)
The discussion surrounding New Approach Methodologies (NAMs), organoids, and organ-on-chip technologies has accelerated rapidly across the pharmaceutical industry in recent years.[1] While much of the public conversation focuses on reducing animal testing, the deeper transformation occurring inside major pharmaceutical companies is far more strategic. The core question is no longer whether organoids are scientifically promising, […]